Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 2/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 11/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 3/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.39 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20038373 | 0.82 | CDK4 (0.41) | KHKADRA2AADRA2BADRA2CCDK4 | |
| SCHEMBL12147196 | 0.81 | CHRNB2 (0.58) | CHRNB2CHRNA4 | |
| SCHEMBL18479402 | 0.80 | KHK (0.48) | KHKADRA2AADRA2BADRA2CCDK4 | |
| SCHEMBL31045828 | 0.79 | KHK (0.47) | KHKADRA2AADRA2BADRA2CCDK4 | |
| SCHEMBL22414247 | 0.79 | CHRNB2 (0.47) | KHKADRA2AADRA2BADRA2CCDK4 | |
| SCHEMBL25949375 | 0.79 | CHRNB2 (0.47) | KHKADRA2AADRA2BADRA2CCDK4 | |
| SCHEMBL2819513 | 0.79 | CHRNB2 (0.47) | KHKADRA2AADRA2BADRA2CCDK4 | |
| SCHEMBL24451824 | 0.78 | KHK (0.52) | KHKADRA2AADRA2BADRA2CMAPT | |
| SCHEMBL26418055 | 0.78 | KHK (0.52) | KHKADRA2AADRA2BADRA2CMAPT | |
| SCHEMBL24478128 | 0.78 | KHK (0.52) | KHKADRA2AADRA2BADRA2CMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | KHK 546/4885ADRA2A 4844/4885ADRA2B 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.